<DOC>
	<DOCNO>NCT00021255</DOCNO>
	<brief_summary>Primary objective : - Compare disease-free survival woman human epidermal growth factor receptor 2 ( HER2 ) -neu-expressing node-positive high-risk node-negative operable breast cancer treat adjuvant doxorubicin , cyclophosphamide , docetaxel without trastuzumab ( Herceptin ) v trastuzumab , docetaxel , carboplatin . Secondary objective : - Compare overall survival participant treat regimen . - Compare toxic effect ( include cardiac ) regimens participant . - Compare quality life participant treat regimen . - Compare pathologic molecular marker predict efficacy regimens participant . - For substudy : Compare peripheral level shed HER2-neu extracellular domain fluorescence situ hybridization predict outcome participant treat regimen .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Trastuzumab Treating Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion criterion : Written inform consent prior begin specific protocol procedure , include expect cooperation participant treatment followup . Accessible treatment followup participate center . Histologically proven breast cancer interval definitive surgery include axillary lymph node involvement assessment registration less equal 60 day . A central pathology review might perform post randomization confirmation diagnosis molecular study . The block use HER2neu determination prior randomization might use central pathology review . Definitive surgical treatment must either mastectomy axillary lymph node involvement assessment , breast conserving surgery axillary lymph node involvement assessment operable breast cancer ( T13 , Clinical N01 , M0 ) . Margins resect specimen definitive surgery must histologically free invasive adenocarcinoma and/or ductal carcinoma situ ( DCIS ) . Participants must either lymph node positive high risk node negative . Lymph node positive participant define participant invasive adenocarcinoma least one axillary lymph node ( pN1 ) show evidence tumor among minimum six resect lymph node . High risk lymph node negative participant define participant invasive adenocarcinoma either 0 ( pNo ) among minimum 6 resect lymph node negative sentinel node biopsy ( pNo ) least one follow factor : tumor size &gt; 2 cm , estrogen receptor ( ER ) and/or progesteron receptor ( PR ) status negative , histologic and/or nuclear grade 23 , age &lt; 35 year . Tumor must show presence HER2neu gene amplification Fluorescence InSitu Hybridization ( FISH analysis ) designate central laboratory . Estrogen and/or progesterone receptor analysis perform primary tumor prior randomization . Results must know time randomization . Karnofsky Performance status index ≥ 80 % . Normal cardiac function must confirm leave ventricular ejection fraction ( LVEF ) ( multiplegated acquisition [ MUGA ] scan ) electrocardiogram ( ECG ) within 3 month prior registration . The result MUGA must equal low limit normal institution . Laboratory requirement : ( within 14 day prior registration ) ) Hematology : ) Neutrophils ≥ 2.0 109/L ii ) Platelets ≥ 100 109/L iii ) Hemoglobin ≥ 10 g/Dl b ) Hepatic function : ) Total bilirubin ≤ 1 UNL ii ) Aspartate aminotransferase ( ASAT ) ( Serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine amino transferase ( ALAT ) ( Serum glutamicpyruvic transaminase [ SGPT ] ) ≤ 2.5 UNL iii ) Alkaline phosphatase ≤ 5 UNL iv ) Participants ASAT and/or ALAT &gt; 1.5 x UNL associate alkaline phosphatase &gt; 2.5 x UNL eligible study . c ) Renal function : ) Creatinine ≤ 175 µmol/L ( 2 mg/dL ) ii ) If creatinine 140 175 μmol/L , calculate creatinine clearance ≥ 60 mL/min . Complete stag workup within 3 month prior registration . All participant bilateral mammography , chest Xray ( posterioanterior [ PA ] lateral ) and/or computerized tomography ( CT ) and/or magnetic resonance imaging ( MRI ) , abdominal ultrasound and/or CT scan and/or MRI , bone scan . In case positive bone scan , bone Xray evaluation mandatory rule possibility metastatic bone scan positivity . Other test may perform clinically indicate . Negative pregnancy test ( urine serum ) within 7 day prior registration woman childbearing potential . An audiology assessment normal result perform within 4 week registration . This center select cisplatin platinum salt choice BCIRG 006 study . Exclusion criterion : Prior systemic anticancer therapy breast cancer ( immunotherapy , hormonotherapy , chemotherapy ) . Prior anthracycline therapy , taxoids ( paclitaxel , docetaxel ) platinum salts malignancy . Prior radiation therapy breast cancer . Bilateral invasive breast cancer . Pregnant , lactate participant . Participants childbearing potential must implement adequate nonhormonal contraceptive measure study treatment ( chemotherapy tamoxifen therapy ) must negative urine serum pregnancy test within 7 day prior registration . Any T4 N2 know N3 M1 breast cancer . Preexisting motor sensory neurotoxicity severity ≥ grade 2 National Cancer Institute ( NCI ) criterion . Cardiac disease would preclude use doxorubicin , docetaxel Herceptin : 1. document myocardial infarction 2. angina pectoris require use antianginal medication 3. history document congestive heart failure 4 . Grade 3 Grade 4 cardiac arrhythmia ( NCI Common Terminology Criteria [ CTC ] , version 2.0 ) 5. clinically significant valvular heart disease 6. participant cardiomegaly chest xray ventricular hypertrophy ECG , unless demonstrate MUGA scan within past 3 month LVEF ≥ low limit normal radiology facility ; 7. participant poorly control hypertension i.e . diastolic great 100 mm/Hg . ( Participants well control medication eligible entry ) 8. participant currently receive medication ( digitalis , betablockers , calcium channelblockers , etc ) alter cardiac conduction , medication administer cardiac arrhythmia , angina congestive heart failure . If medication administer reason ( ie hypertension ) , participant eligible . Other serious illness medical condition : 1. history significant neurologic psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding give informed consent 2. active uncontrolled infection 3. active peptic ulcer , unstable diabetes mellitus 4. impaired hearing ( participant treat center select cisplatin platinum salt choice ) Past current history neoplasm breast carcinoma , except : 1. curatively treated nonmelanoma skin cancer 2. situ carcinoma cervix 3. cancer curatively treat evidence disease least 10 year 4. ipsilateral DCIS breast 5. lobular carcinoma insitu ( LCIS ) breast Current therapy hormonal agent raloxifene , tamoxifen , selective estrogen receptor modulators ( SERMs ) , either osteoporosis prevention . Participants must discontinue agent prior randomization . Chronic treatment corticosteroid unless initiate &gt; 6 month prior study entry low dose ( ≤ 20 mg methylprednisolone equivalent ) . Concurrent treatment ovarian hormonal replacement therapy . Prior treatment must stop prior randomization . Definite contraindication use corticosteroid . Concurrent treatment experimental drug . Participation another clinical trial investigational market drug within 30 day prior study entry . Concurrent treatment anticancer therapy . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>